25 results
IDSA Recommendations for Preventing and Treating Penicillium marneffei Infections in HIV-AIDS
Preventing 1st Episode of Penicilliosis (Primary
Recommendations for Preventing ... Infections in HIV-AIDS Preventing ... #Treatment #management ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing Human Papillomavirus Infections and Cervical Cancer Screening for Women with in HIV-AIDS
Recommendations
Recommendations for Preventing ... Preventing First ... #Treatment #management ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Chagas Disease (American Trypanosomiasis) in HIV-AIDS
Preventing Clinical Disease
Indication:  Individuals
Recommendations for Preventing ... ) in HIV-AIDS Preventing ... #Treatment #management ... opportunistic #infections #HIVAIDS ... #pharmacology
Outpatient Treatment of with Community-Acquired Pneumonia (CAP)
No comorbidities or risk factors for MRSA or Pseudomonas aeruginosa:
Acquired #Pneumonia #Antibiotics ... Treatment #Regimen #Management ... #Guidelines #pharmacology
IDSA Recommendations for Preventing and Treating Bacterial Enteric Infections in HIV-AIDS
Preventing Bacterial Enteric Illness:
 • Antimicrobial
Recommendations for Preventing ... Infections in HIV-AIDS Preventing ... #Treatment #management ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Preventing and Treating Toxoplasma gondii Encephalitis in HIV-AIDS
Indications for Initiating Primary Prophylaxis:
 •
Recommendations for Preventing ... Encephalitis #IDSA #Prevention ... opportunistic #infections #HIVAIDS ... #management #pharmacology ... #pharmacology
Optimal Use of Polymixin Antibiotics - ACCP Clinical Practice Guidelines 2019

#PolymixinB #Polymixin #Colistin #Pharmacology #Management #Antibiotics
Use of Polymixin Antibiotics ... Clinical Practice Guidelines ... Polymixin #Colistin #Pharmacology ... #Management #Antibiotics
IDSA Recommendations for Treating Mucosal Candidiasis in HIV-AIDS
Oropharyngeal Candidiasis: Initial Episodes (Duration of Therapy: 7–14 days)
Preferred
mucosal #IDSA #Prevention ... #Treatment #management ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA Recommendations for Treating Visceral and Cutaneous Leishmaniasis in HIV-AIDS
Treating Visceral Leishmaniasis - Preferred Therapy:
 •
Leishmaniasis #Prevention ... #Treatment #management ... opportunistic #infections #HIVAIDS ... #pharmacology
IDSA 2017 CDiff Guidelines - Table 7. Potential Treatment Agents for Treatment of the Primary Clostridium difficile
IDSA 2017 CDiff Guidelines ... infection Episode #Pharmacology ... #Management #CDiff ... IDSA2017 #Adjunct #Antibiotics